DualityBio and Genentech agreed to a collaboration and license deal centered on DUPAC, DualityBio’s next-generation ADC payload platform aimed at overcoming resistance seen with topoisomerase inhibitor–based conjugates. The structure includes $45 million upfront and potential milestone payments exceeding $1 billion, with Genentech taking over global late-stage development and commercialization. The agreement comes with a clear commercial thesis: earlier ADC successes have expanded the treatment pool, and resistance is increasingly driving unmet needs. For payload developers, the deal signals Genentech’s willingness to underwrite platform-level innovation rather than single-asset bets.